Combined immuno-chemotherapy (R-CHOP) results in significantly superior response rates and time to treatment failure in first line treatment of patients with lymphomplasmocytoid/ic immumocytoma (LP-IC) -: Results of a prospective randomized trial of the German Low grade Lymphoma Study Group (GLSG).

被引：7

作者：

Buske, C

Dreyling, MH

Eimermacher, H

Boeck, HP

Pfreundschuh, M

Metzner, B

Fuchs, R

Woermann, B

Truemper, LH

Hess, G

Wandt, H

Ludwig, WD

Kreuser, ED

Schimke, J

Weh, HJ

Schmitz, S

Schmiegel, W

Unterhalt, M

Hiddemann, W

机构：

[1] Univ Hosp Grosshadern, Dept Med 3, Munich, Germany

[2] Catholic Hosp Hagen, Dept Med 2, Hagen, Germany

[3] Practice Hem Onc, Offenbach, Germany

[4] Univ Saarland, Sch Med, Dept Med 1, D-6650 Homburg, Germany

[5] Hosp Oldenburg, Dept Med 2, Oldenburg, Germany

[6] St Antonius Hosp, Dept Hematol Oncol, Eschweiler, Germany

[7] City Hosp Braunschweig, Dept Med, Braunschweig, Germany

[8] Univ Gottingen, Dept Hematol Oncol, D-3400 Gottingen, Germany

[9] Univ Mainz, Dept Med 3, D-6500 Mainz, Germany

[10] Hosp Nuernberg N, Dept Med 5, Nurnberg, Germany

[11] Humboldt Univ, Robert Roessle Clin, Charite, Berlin, Germany

[12] Hosp Barmherzige Brueder, Dept Hematol Oncol, Regensburg, Germany

[13] Practice Hem Onc, Saarbrucken, Germany

[14] Franziskus Hosp, Dept Hematol Oncol, Bielefeld, Germany

[15] Practice Hem Onc, Cologne, Germany

[16] Med Univ Hosp, Dept Hematol Oncol, Bochum, Germany

来源：

BLOOD | 2004年 / 104卷 / 11期

关键词：

D O I：

10.1182/blood.V104.11.162.162

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

162

引用

页码：50A / 50A

页数：1